Myriad RBM DiscoveryMAP

Discover Myriad RBM’s Track to Success.

“Despite the known benefits of biomarkers in drug development, many biomarker discovery efforts fail because the initial patterns generated in discovery do not reproduce on a platform analytically validated to clinical laboratory standards. The Myriad RBM approach discovers new biomarker patterns that later validate on the same platform which is then used in clinical trials.”
— Ralph McDade, President, Myriad RBM

Human DiscoveryMAP®

Subsets of DiscoveryMAP:

Comprehensive Value

DiscoveryMAP is a comprehensive, quantitative, immunoassay service product, measuring our complete menu of more than 300 human assays. It is the culmination of 15 years of assay development for cytokines, chemokines, metabolic markers, hormones, growth factors, tissue remodeling proteins, angiogenesis markers, acute phase reactants, cancer markers, kidney damage markers, CNS biomarkers and other important circulating proteins. DiscoveryMAP is for those who seek a thorough understanding of a compound’s biological activity, efficacy, and safety profile as well as the disease or condition being addressed.

The DiscoveryMAP service products help increase the odds of identifying novel protein biomarker patterns in drug development or diagnostic discovery projects. This data can support critical go/no-go decisions or identify candidate panels for potential companion diagnostics. Once a pattern is discovered, we can seamlessly convert those biomarkers into a CustomMAP for high volume sample processing resulting in better, more efficient clinical trials.

Myriad RBM Quality

DiscoveryMAP samples are tested on an automated platform in Myriad RBM’s CLIA-certified laboratory using proprietary reagents and software. Validation of Myriad RBM’s assays is guided by clinical laboratory standards and is designed to provide accurate and reproducible biomarker measurements. This enables the discovery of patterns made up of multiple biomarkers, many with small, yet reproducibly detectable changes. Multiplexing allows all of these assays to be performed using less than 1 milliliter of serum or plasma, as compared to single-plex platforms, such as ELISA, which would require milliliters.

Talk to a scientist about the biomarker arm of your study.

DiscoveryMAP analyte categories:

  • Cytokines
  • Chemokines
  • Metabolic
  • Hormones
  • Toxicology
  • Growth Factors
  • Serum Proteins
  • Acute Phase Reactants
  • Angiogenesis
  • Tissue Remodeling
See all 300+ analytes